Ulcerative Colitis and Vedolizumab: What You Need to Know About Surgical Outcomes
"A comprehensive look at the safety of vedolizumab in ulcerative colitis patients undergoing surgery, including risks, benefits, and factors to consider."
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that can significantly impact a person's quality of life. While medication can help manage symptoms, nearly a third of individuals with UC may eventually require surgery to remove the colon.
Vedolizumab has emerged as a popular and effective treatment option for UC. However, questions remain about its safety when surgery is necessary. Specifically, there is concern about whether vedolizumab increases the risk of post-operative complications, such as infections or problems with the surgically created pouch.
This article examines the current research on vedolizumab and surgical outcomes in UC patients. We'll explore potential risks and benefits, offering a balanced perspective to help you make informed decisions about your care.
Current Evidence on Surgical Outcomes
Evidence on vedolizumab and ulcerative colitis surgery remains focused on postoperative outcomes. One study identified 25 procedures involving vedolizumab exposure and used 1:3 matching based on age, gender, and number of surgical stages; among 77 patients treated without biologics, 54 were eligible for matching. A separate study evaluated 30-day postoperative morbidity among patients undergoing abdominal colectomy after preoperative vedolizumab exposure, drawing on 285 patients treated between 2007 and 2017. Other research has examined vedolizumab's long-term clinical and endoscopic outcomes in Chinese real-world practice, while VISIBLE 1 and 2 analyses have reported hospitalizations and surgeries among patients receiving subcutaneous vedolizumab.
Clinical Decision-Making
Management of ulcerative colitis generally requires balancing disease control, medication risks, and the possibility of surgery. Decisions about vedolizumab around an operation may depend on disease severity, prior treatment, surgical timing, and the patient's overall condition. However, the available evidence may not provide a single universally accepted approach, particularly when studies differ in design and patient populations. Treatment planning therefore requires individualized discussion between the patient, gastroenterologist, and surgical team.
From Immunosuppression to Targeted Therapy
Ulcerative colitis is a chronic relapsing and remitting inflammatory bowel disease characterized by leukocytic infiltration of the mucosa. Its therapeutic goals include inducing remission, maintaining remission, and ideally achieving mucosal healing. Immunosuppression, including anti-TNF-alpha therapy, became a mainstay for many patients, while vedolizumab introduced a more targeted treatment approach. The US Food and Drug Administration approved vedolizumab in May 2014; the product is marketed as Entyvio, with the first approval recorded on May 20, 2014.
Is Vedolizumab Safe Before Surgery for Ulcerative Colitis?
A recent study published in Inflammatory Bowel Diseases investigated the surgical outcomes of UC patients who received vedolizumab within 12 weeks of their operation. The researchers compared these patients to those treated with anti-TNFa medications, another class of biologics commonly used for UC.
- Superficial Surgical Site Infections: Patients receiving vedolizumab had a higher rate of superficial surgical site infections (SSI).
- Mucocutaneous Separation: There was also a greater incidence of mucocutaneous separation at the ileostomy site in the vedolizumab group.
- Overall Infectious Complications: Importantly, the study found no significant difference in the overall surgical infectious complication rate, deep space SSI, 30-day hospital readmission, or return to the operating room between the two groups.
Evolving Evidence
Recent research continues to evaluate vedolizumab in real-world ulcerative colitis care and in relation to surgical outcomes. Studies may differ in their populations, treatment settings, endpoints, and follow-up periods, so their results should be interpreted in context. The current literature supports continued investigation rather than a definitive conclusion that applies to every patient. Clinicians must therefore integrate emerging evidence with individual clinical circumstances.
Remaining Uncertainty
The principal limitation in this area is uncertainty about how preoperative vedolizumab exposure relates to postoperative complications. Observational studies can be affected by differences in disease severity, prior therapies, surgical urgency, and patient selection. A treatment associated with surgery may therefore reflect the characteristics of patients who required surgery rather than a direct medication effect. These limitations make it difficult to interpret isolated findings as proof of either harm or safety.
Vedolizumab Compared With Other Therapies
Comparative treatment decisions remain difficult because there are relatively few head-to-head trials among targeted inflammatory bowel disease therapies. In a cohort of 3,263 biologic-naive patients with ulcerative colitis followed for up to five years, hospitalization and surgery burdens did not differ significantly between vedolizumab and TNF antagonists. The same cohort reported that a vedolizumab-first strategy was associated with more time in corticosteroid-free disease stability than a TNF-antagonist-first strategy. Other real-world research has compared vedolizumab with ustekinumab using steroid-free clinical remission at week 16, including patients previously exposed to at least one anti-TNF treatment.
Making Informed Decisions About Your UC Care
The study provides valuable insights into the safety of vedolizumab in the perioperative period for UC patients. While there may be a slightly increased risk of superficial surgical site infections, the overall risk of infectious complications does not appear to be significantly elevated. However, the decision to continue or discontinue vedolizumab before surgery should be made in consultation with your healthcare team, considering your individual risk factors and disease severity.
Interpreting Surgical Risk
The effect of preoperative vedolizumab on postoperative complications remains controversial. A meta-analysis reviewed available studies comparing inflammatory bowel disease patients who received vedolizumab before surgery with those who did not. Earlier work also described perioperative safety as unclear and evaluated early postoperative complications in vedolizumab-treated patients undergoing nonintestinal operations. Taken together, these sources support careful interpretation of the evidence rather than a simple assumption that vedolizumab either causes or prevents surgical complications.
Personalized Treatment and Long-Term Safety
Future research is increasingly focused on biologic-naive populations and personalized frontline treatment. In China, infliximab and vedolizumab were approved for ulcerative colitis around 2020, creating an opportunity to study initial vedolizumab selection in real-world care. Broader treatment approaches have also shifted over the past decade from step-up and top-down strategies toward treat-to-target algorithms. A postauthorization safety study has additionally compared the long-term safety of vedolizumab with other biologics in patients with ulcerative colitis or Crohn's disease.
Care Beyond a Single Drug
Ulcerative colitis care is shaped by more than the choice of one medication. Treatment decisions must account for disease control, medication exposure, surgical considerations, monitoring, and the availability of specialized care. Evidence gaps can make it difficult to compare options consistently across healthcare settings. These systemic challenges reinforce the need for coordinated, individualized planning.
Individualized Patient Decisions
For patients, the question is not simply whether vedolizumab is effective, but how its potential benefits and uncertainties fit with personal treatment goals and surgical needs. Discussions may include the possibility of hospitalization or surgery, the timing of therapy, and concerns about postoperative recovery. Because published studies represent groups rather than identical individuals, clinicians must explain how closely the evidence matches a particular patient. Shared decision-making remains important when evidence about perioperative safety is incomplete.